Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna Stock Plummets 17% on 2025 Sales Guidance Slash

The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.

MRKNegative Net Change MRNAPositive Net Change CTMXPositive Net Change CSTLNegative Net Change

Zacks Equity Research

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek

The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.

VRTXNo Net Change MRNAPositive Net Change CTMXPositive Net Change CSTLNegative Net Change

Sundeep Ganoria

Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?

Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.

GSKPositive Net Change PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change

Zacks Equity Research

NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines

Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.

SNYNegative Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change